bluebird bioNASDAQ: BLUE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Blue Owl Capital Corporation III (“OBDE” or the “Company”) (NYSE: OBDE) and Blue Owl Capital Corporation (NYSE: OBDC). Under the terms of the proposed transaction, shareholders of OBDE will receive newly issued shares of OBDC for each share of OBDE based on an exchange ratio determined prior to closing. KSF.

bluebird bio Inc (NASDAQ:BLUE) shares shed more than 11% on Friday after the Massachusetts-based biotech company developing gene therapies for severe genetic diseases was downgraded by Bank of America analysts. The analysts downgraded the company to ‘Neutral' and lowered their price target to $0.50 from $3 on their belief its key product launch, Lyfgenia for sick cell disease (SCD), will ramp slower and achieve lower peak revenue.

Bluebird Bio (BLUE, Financial) experienced a significant drop in its stock price, declining by 5.67%. The shares are currently trading at $0.491, with a trading volume of 3.72 million shares, a turnover rate of 1.92%, and showing a price amplitude of 4.76%.

Bluebird Bio (BLUE, Financial) stock experienced a notable surge of 5.04% to $0.494 per share. The trading volume reached 6.47552 million shares, resulting in a turnover rate of 3.34% and a volatility of 8.69%.

Gene therapy maker bluebird bio said on Tuesday it would cut 25% of its workforce as part of a restructuring program for cost reduction.

There's a trade that's generally accepted anytime someone makes an investment.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Blue Owl Capital Corporation III (“OBDE” or the “Company”) (NYSE: OBDE) and Blue Owl Capital Corporation (NYSE: OBDC). Under the terms of the proposed transaction, shareholders of OBDE will receive newly issued shares of OBDC for each share of OBDE based on an exchange ratio determined prior to closing. KSF.

Shareholder Convertible Debenture, Government of Canada SOFII Loan and BDC Bank support is part of funding Shareholder Convertible Debenture, Government of Canada SOFII Loan and BDC Bank support is part of funding

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation concerns whether the board of directors of Blue have breached their fiduciary duties to the company.